Distinguished in Sandhoff Disease

Andreas Hahn

Bernhard Nocht Str. 74, 
Hamburg, HH, DE 
Distinguished in Sandhoff Disease
Bernhard Nocht Str. 74, 
Hamburg, HH, DE 
OverviewLocationsClinical Research

Overview

Andreas Hahn practices in Hamburg, Germany. Mr. Hahn is rated as a Distinguished expert by MediFind in the treatment of Sandhoff Disease. His top areas of expertise are Pompe Disease, Noonan Syndrome, Sandhoff Disease, Deep Brain Stimulation, and Hormone Replacement Therapy (HRT).

His clinical research consists of co-authoring 510 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 2 clinical trials in the study of Sandhoff Disease.

Gender
Male

Locations

Bernhard Nocht Str. 74, Hamburg, HH 20359, Germany
Other Locations
Rudolf Buchheim Str. 8, Giessen, HE 35392, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study
Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: N-Acetyl-L-Cysteine
Study Phase: Phase 2
Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care
Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care
Enrollment Status: Active_not_recruiting
Publish Date: March 14, 2025
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Enrollment Status: Terminated
Publish Date: December 30, 2024
Intervention Type: Drug
Study Drug: Venglustat GZ402671
Study Phase: Phase 3
Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study
Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: IB1001
Study Phase: Phase 2
Effects of N-Acetyl-L-Leucine on Niemann Pick Type C Disease: A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study.
Effects of N-Acetyl-L-Leucine on Niemann Pick Type C Disease: A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study.
Enrollment Status: Completed
Publish Date: November 28, 2023
Intervention Type: Drug
Study Phase: Phase 2
European Alpha-Mannosidosis Participant: An International, Multicenter, Epidemiological Protocol
European Alpha-Mannosidosis Participant: An International, Multicenter, Epidemiological Protocol
Enrollment Status: Terminated
Publish Date: June 13, 2022
View 5 Less Clinical Trials

510 Total Publications

Corrigendum to "High association of MOG-IgG antibodies in children with bilateral optic neuritis" [Eur. J. Paediatr. Neurol. 27 (2020) 86-93].
Corrigendum to "High association of MOG-IgG antibodies in children with bilateral optic neuritis" [Eur. J. Paediatr. Neurol. 27 (2020) 86-93].
Journal: European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
Published: October 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hahn's expertise for a condition
ConditionClose
View All 34 Advanced Conditions
View All 126 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile